Prolonged Survival of Subcutaneous Allogeneic Islet Graft by Donor Chimerism without Immunosuppressive Treatment

Table 1

Donor chimerism achieved in the peripheral blood of mice that received conditioning and bone marrow cell and/or mesenchymal stem cell transplantation.

Donor chimerism (%)	Group A; Renal site; ()		Group B; Subcutaneous site; ()		Group D; Subcutaneous site; ()
Time	2 weeks	8 weeks	2 weeks	8 weeks	2 weeks	8 weeks
CD4	61.6 ± 8.9	98.8 ± 0.5	69.4 ± 12.9	98.7 ± 1.2	0.3 ± 0.1	1.6 ± 0.5
CD8	94.0 ± 0.9	97.2 ± 0.4	91.2 ± 3.4	98.3 ± 0.9	4.8 ± 3.0	4.1 ± 1.7
CD45	94.3 ± 2.1	99.0 ± 0.4	94.8 ± 5.2	99.7 ± 0.1	3.3 ± 3.1	0.1 ± 0.0
CD11b	94.2 ± 0.8	96.6 ± 2.6	94.4 ± 4.4	98.8 ± 0.2	3.8 ± 3.6	0.8 ± 0.2
CD11c	56.6 ± 8.3	81.5 ± 1.5	62.3 ± 4.4	74.1 ± 3.0	2.1 ± 1.1	1.9 ± 0.7
CD19	90.5 ± 2.6	98.6 ± 0.1	86.8 ± 9.1	98.2 ± 0.7	2.4 ± 2.0	2.1 ± 0.7
Gr1	90.5 ± 1.4	96.2 ± 1.2	92.6 ± 5.0	97.8 ± 0.3	2.3 ± 2.0	1.8 ± 0.4
Foxp3	30.8 ± 9.3	58.1 ± 1.6	38.1 ± 1.4	50.8 ± 1.8	9.1 ± 3.4	9.4 ± 0.4

Chimerism in the BALB/c mice was detected by staining for H-2D^b-expressing (C57BL/6 donor) cells that were distinguishable from BALB/c cells expressing H-2D^d at 2 and 8 weeks posttransplantation. Other antibodies used for chimerism analysis included CD45, CD4, CD8, CD11b, CD11c, CD19, Ly6G/6C (Gr1), and Foxp3. All comparisons between group A and group B did not differ. All comparisons between group B and group D were statistically significant and had a value of less than 0.001.